11 citations
,
October 2018 in “Pediatric dermatology” Leflunomide and anthralin may effectively treat severe alopecia areata.
January 2019 in “FarFar - Pharmacy Repository” Microemulsions improve adapalene's skin absorption for better acne treatment.
July 2018 in “British Journal of Dermatology” Hair regrowth was seen in 83% of children with alopecia, immune system plays a role in the condition, and various treatments showed effectiveness for hair and nail disorders.
18 citations
,
January 2021 in “Theranostics” The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
August 2025 in “Journal of Cosmetic Dermatology” The dietary supplement AGA-P improves the effectiveness of hair loss treatments.
33 citations
,
November 2020 in “AAPS PharmSciTech”
1 citations
,
October 2025 in “Nano Research” A new microneedle patch effectively treats atopic dermatitis by reducing skin stress and restoring immune balance.
May 2018 in “Más dermatología” The higher dose supplement was more effective in treating female hair loss.
June 2024 in “Archives of Medical Science” Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.
7 citations
,
October 2012 in “PubMed” Triamcinolone regrows hair better but relapses more than anthralin.
January 2021 in “Asian Journal of Research in Dermatological Science” September 2025 in “Journal of the American Academy of Dermatology” Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
31 citations
,
March 2014 in “Journal of the European Academy of Dermatology and Venereology” BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.
December 2025 in “Actas Dermo-Sifiliográficas” Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
April 2023 in “Journal of Investigative Dermatology” ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
Combining Minoxidil with topical Dutasteride via microneedling is the most effective and safe treatment for hair loss.
September 2022 in “Journal of the American Academy of Dermatology” The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
January 2026 in “International Journal of Dermatology Venereology and Leprosy Sciences” Intradermal dutasteride effectively and safely improves hair growth in early-stage androgenetic alopecia.
4 citations
,
February 2025 in “Molecular Medicine” 5-aminolevulinic acid therapy reduces acne by decreasing fat production in skin cells.
November 2021 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” The document does not give specific results for hair loss treatment effectiveness.
August 2025 in “International Journal of Pharmaceutical Sciences and Nanotechnology” The new minoxidil nanoemulgel may treat hair loss more effectively with fewer side effects.
April 2024 in “Journal of translational medicine” Melanocytes are important for normal body functions and have potential uses in regenerative medicine and disease treatment.
4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
98 citations
,
January 2013 in “Journal of The American Academy of Dermatology” Dutasteride may help stabilize Frontal Fibrosing Alopecia, but more research is needed.
1 citations
,
May 2017 in “Journal of cosmetic and laser therapy” Lasers can help reduce skin side effects from cancer treatment.
May 2025 in “International Journal of Trichology” Topical tofacitinib may help regrow hair in children with alopecia totalis.
227 citations
,
April 2023 in “The Lancet” Ritlecitinib effectively treats alopecia areata and is well-tolerated.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.